Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study-Reference-Cited by-同舟云学术

Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study

Published:2016-12-01 Issue:1 Volume:6 Page:100-108
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Kwon Jihyun¹,Min Chang-Ki²,Kim Kihyun³,Han Jae-joon⁴,Moon Joon Ho⁵,Kang Hye Jin⁶,Eom Hyeon-Seok⁷,Kim Min Kyoung⁸,Kim Hyo Jung⁹,Yoon Dok Hyun¹⁰,Lee Jeong-Ok¹¹,Lee Won Sik¹²,Lee Jae Hoon¹³,Lee Je-Jung¹⁴,Choi Yoon-seok¹⁵,Kim Sung hyun¹⁶,Yoon Sung-soo¹⁷

Affiliation:

1. Department of Internal Medicine; Chungbuk National University Hospital; Cheongju Korea

2. Department of Internal Medicine; Seoul St. Mary's Hospital; The Catholic University of Korea; Korea

3. Department of Internal Medicine; Samsung Medical Center; Sungkyunkwan University School of Medicine; Korea

4. Departments of Hematology-Oncology; School of Medicine; Kyung Hee University; Seoul Korea

5. Department of Internal Medicine; Kyungpook National University Hospital; Daegu Korea

6. Department of Internal Medicine; Korea Cancer Center Hospital; Seoul Korea

7. Hematology-Oncology Clinic; National Cancer Center; Goyang-si Korea

8. Department of Internal Medicine; Yeungnam University Medical Center; Daegu Korea

9. Department of Internal Medicine; Hallym University Sacred Heart Hospital; Hallym University College of Medicine; Anyang Korea

10. Department of Oncology; Asan Medical Center; University of Ulsan, College of Medicine; Seoul Korea

11. Department of Internal Medicine; Seoul National University Bundang Hospital; Seongnam Korea

12. Department of Hemato-Oncology; Inje University Busan Paik Hospital; Busan Korea

13. Department of Internal Medicine; Gachon University Gil Hospital; Incheon Korea

14. Department of Hematology-Oncology; Chonnam National University Hwasun Hospital; Jeollanamdo Korea

15. Department of Internal Medicine; Chungnam National University Hospital; Daejeon Korea

16. Department of Internal Medicine; Dong-A Medical Center; Dong-A University College of Medicine; Busan Korea

17. Department of Internal Medicine; Seoul National University Hospital; Seoul Korea

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Reference35 articles.

1. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials;Pasquali;Myeloma Trialists'Collaborative Group. J. Clin. Oncol.,1998

2. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma;Child;N. Engl. J. Med.,2003

3. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome;Attal;N. Engl. J. Med.,1996

4. Dexamethasone + thalidomide (Dex/Thal) compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (MM): a randomized trial;Macro;Blood (ASH Annual Meeting Abstracts),2006

5. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma;Rajkumar;J. Clin. Oncol.,2008

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What’s Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma;Targeted Oncology;2022-06-30

2. Treatment of relapsed and refractory multiple myeloma;BLOOD RESEARCH;2020-07-31

3. Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study;Clinical Lymphoma Myeloma and Leukemia;2020-02

4. A Mini-Review on Thalidomide: Chemistry, Mechanisms of Action, Therapeutic Potential and Anti-Angiogenic Properties in Multiple Myeloma;Current Medicinal Chemistry;2017-09-14

5. Cyclophosphamide/dexamethasone/thalidomide;Reactions Weekly;2017-04